Table 1 Patient characteristics by BDX008 classification for all patients and by BRAF status
All patients (N = 71) | BRAF WT (N = 39) | BRAF MUT (N = 25) | ||||
|---|---|---|---|---|---|---|
BDX008+ (N = 30) | BDX008- (N = 41) | BDX008+ (N = 15) | BDX008- (N = 24) | BDX008+ (N = 12) | BDX008- (N = 13) | |
Age | ||||||
Median (Range) | 59 (28–86) | 66 (32–80) | 59 (34–86) | 61 (44–80) | 52 (29–69) | 67 (32–78) |
Gender, n (%) | ||||||
Female | 16 (53) | 19 (46) | 8 (53) | 10 (42) | 7 (58) | 7 (54) |
Male | 14 (47) | 22 (54) | 7 (47) | 14 (58) | 5 (42) | 6 (46) |
BRAF Status, n (%) | ||||||
Mutation | 12 (40) | 13 (32) | 0 (0) | 0 (0) | 12 (100) | 13 (100) |
Wild Type | 15 (50) | 24 (59) | 15(100) | 24(100) | 0 (0) | 0 (0) |
NA | 3 (10) | 4 (10) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Line of Therapy with anti-PD-1, n (%) | ||||||
1st | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
2nd | 4(13) | 13 (32) | 3 (20) | 9 (38) | 0 (0) | 3 (23) |
3rd | 17(57) | 16 (39) | 11 (73) | 11 (46) | 5 (42) | 3 (23) |
4th | 4 (13) | 10 (24) | 1 (7) | 4 (17) | 3 (25) | 6 (46) |
5th and higher | 4 (13) | 2 (5) | 0 (0) | 0 (0) | 4 (33) | 1(8) |
Targeted therapy, n (%) | ||||||
No | 18 (60) | 28 (68) | 14 (93) | 22 (92) | 2 (15) | 1 (8) |
Yes | 12 (40) | 13 (32) | 1 (7) | 2 (8) | 11 (85) | 11 (92) |
Anti-PD-1 agent, n (%) | ||||||
Nivolumab | 9 (30) | 15 (37) | 6 (40) | 10 (42) | 1 (8) | 4 (31) |
Pembrolizumab | 21 (70) | 26 (62) | 9 (60) | 14 (58) | 11 (92) | 9 (69) |
NLR, n (%) | ||||||
<5 | 25 (83) | 19 (46) | 14 (93) | 12 (50) | 8 (67) | 5 (38) |
≥5 | 5 (17) | 22 (54) | 1 (7) | 12 (50) | 4 (33) | 8 (62) |
LDH | ||||||
Median (in IU/l) | 402 | 617 | 379 | 525 | 416 | 728 |
NA, n (%) | 5 (17) | 2 (5) | 3 (20) | 2 (8) | 2 (17) | 0 (0) |
<2ULNa, n (%) | 22 (73) | 21 (51) | 12 (80) | 15 (63) | 7 (58) | 5 (38) |
2ULNa, n (%) | 3 (10) | 18 (44) | 0 (0) | 7 (29) | 3 (25) | 8 (62) |
Melanoma Type, n (%) | ||||||
cutaneous | 22 (73) | 24 (59) | 11 (73) | 14 (58) | 10 (83) | 9 (69) |
mucosal | 2 (7) | 1 (2) | 2 (13) | 1 (4) | 0 (0) | 0 (0) |
SPI | 2 (7) | 2 (5) | 1 (7) | 1 (4) | 1 (8) | 0 (0) |
uveal | 2 (7) | 4 (10) | 0 (0) | 3 (13) | 0 (0) | 0 (0) |
NA | 2 (7) | 10 (24) | 1 (7) | 5 (21) | 1 (8) | 4 (31) |